Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 8/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400828 | 0.95 | NTMT1 (0.46) | NTMT1CHRNA7BCHEACHECHRM3 | |
| SCHEMBL29415421 | 0.83 | NTMT1 (0.55) | NTMT1CHRNA7BCHEACHECHRM3 | |
| SCHEMBL19837256 | 0.82 | NTMT1 (0.54) | NTMT1 | |
| SCHEMBL29397422 | 0.78 | NTMT1 (0.44) | NTMT1CHRNA7BCHEACHECHRM3 | |
| SCHEMBL29356650 | 0.77 | NTMT1 (0.55) | NTMT1 | |
| SCHEMBL15577980 | 0.77 | NTMT1 (0.55) | NTMT1 | |
| SCHEMBL16943615 | 0.77 | NTMT1 (0.55) | NTMT1 | |
| SCHEMBL19837241 | 0.76 | NTMT1 (0.80) | NTMT1 | |
| SCHEMBL15578348 | 0.75 | ACACB (0.49) | — | |
| SCHEMBL16933657 | 0.75 | CHRM5 (0.41) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | NTMT1 754/4885CHRNA7 4254/4885BCHE 1228/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885CHRNA7 4631/4885BCHE 972/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885CHRNA7 4631/4885BCHE 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.